Loading stock data…
$1.98-0.08 (-3.88%)
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease.
Acumen Pharmaceuticals, Inc. in the Healthcare sector is trading at $2.00 with a market capitalization of $148M. Wall Street consensus targets $7.60 (5 analysts), implying a +281.0% move over the next 12 months. The stock is currently 45% below its 52-week high of $3.60, remaining 20.2% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$32.56M↓ | -$21.15M↑ | -$25.20M↑ | -$26.51M↑ | -$41.75M |
| Net Income | -$32.72M↓ | -$20.74M↑ | -$25.14M↑ | -$26.45M↑ | -$40.95M |
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phas...